Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Global Market Report 2026

Description

Asthma and chronic obstructive pulmonary disease (COPD) drugs are medications used to treat and manage respiratory conditions that cause difficulty in breathing. They work by reducing inflammation, relaxing airway muscles, and improving airflow to the lungs, alleviating symptoms such as wheezing, coughing, and shortness of breath. These medications are commonly administered via inhalers or nebulizers to ensure effective delivery to the lungs.

The main drug classes for asthma and COPD include bronchodilators, corticosteroids, combination drugs, and leukotriene modifiers. Bronchodilators act by quickly relaxing airway muscles to widen breathing passages, providing rapid relief from asthma and COPD symptoms. These drugs can be administered through inhalation, oral, injection, nasal, and other routes. They are prescribed to adults, pediatric, and geriatric patients for conditions such as asthma, COPD, allergic rhinitis, and pulmonary hypertension. Distribution occurs through hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.

Tariffs have affected the asthma and COPD drugs market by increasing the cost of APIs, inhaler components, and biologic ingredients used in bronchodilators, corticosteroids, and combination therapies. Inhalation-based drugs and biologics are most impacted, particularly in North America and Europe, which rely on global pharmaceutical and device supply chains. At the same time, tariffs are promoting domestic inhaler manufacturing and local API production, improving long-term market resilience.

The asthma and chronic obstructive pulmonary disease (copd) drugs market research report is one of a series of new reports from The Business Research Company that provides asthma and chronic obstructive pulmonary disease (copd) drugs market statistics, including asthma and chronic obstructive pulmonary disease (copd) drugs industry global market size, regional shares, competitors with a asthma and chronic obstructive pulmonary disease (copd) drugs market share, detailed asthma and chronic obstructive pulmonary disease (copd) drugs market segments, market trends and opportunities, and any further data you may need to thrive in the asthma and chronic obstructive pulmonary disease (copd) drugs industry. This asthma and chronic obstructive pulmonary disease (copd) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The asthma and chronic obstructive pulmonary disease (copd) drugs market size has grown strongly in recent years. It will grow from $35.66 billion in 2025 to $39.07 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to rising smoking prevalence, urban air pollution, hospital-based respiratory care, inhaler technology adoption, growth in asthma diagnosis.

The asthma and chronic obstructive pulmonary disease (copd) drugs market size is expected to see strong growth in the next few years. It will grow to $55.67 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to biologic drug innovation, aging population, air quality deterioration, personalized respiratory medicine, homecare respiratory solutions. Major trends in the forecast period include increased use of combination inhaler therapies, growing adoption of long-acting bronchodilators, expansion of biologic therapies for severe asthma, shift toward home-based respiratory management, rising demand for generic inhalation drugs.

The rising prevalence of smoking is expected to drive the growth of the asthma and COPD drugs market in the coming years. Smoking, the habit of inhaling tobacco smoke, can lead to severe health issues, including lung cancer and heart disease. The increase in smoking is largely influenced by social factors such as peer pressure, cultural norms, and environmental encouragement to start and continue the habit. Asthma and chronic obstructive pulmonary disease (COPD) drugs help counteract the respiratory damage caused by smoking by reducing inflammation, relaxing airway muscles, and improving airflow, thereby alleviating symptoms and enhancing lung function. For example, in 2024, the European Respiratory Society (ERS), a Switzerland-based non-profit organization, reported that smoking rates among young people rose from 22.5% in 2022 to 40.1% in 2024. Therefore, the increasing prevalence of smoking is fueling growth in the asthma and COPD drugs market.

Key companies in the asthma and COPD drugs market are focusing on innovative combination therapies, such as short-acting beta-agonist (SABA) and inhaled corticosteroid (ICS) rescue inhalers, to improve disease management, prevent severe asthma attacks, and enhance inflammation control. A SABA-ICS rescue inhaler combines a short-acting beta-agonist, which quickly relaxes airway muscles to relieve symptoms, with an inhaled corticosteroid, which reduces airway inflammation. This dual-action approach provides immediate symptom relief while addressing the underlying inflammatory condition. For instance, in January 2024, AstraZeneca, a UK-based biopharmaceutical company, launched AIRSUPRA (albuterol/budesonide) in the US, a fixed-dose SABA-ICS rescue inhaler delivered via pressurised metered-dose inhaler (pMDI) Aerosphere technology. AIRSUPRA offers acute symptom relief while simultaneously reducing airway inflammation, lowering the risk of severe asthma exacerbations, and improving overall asthma control.

In February 2024, GSK plc, a UK-based pharmaceutical company, acquired Aiolos Bio for an undisclosed amount. This acquisition aims to expand GSK's asthma and respiratory biologics portfolio by incorporating Aiolos Bio's investigational therapy, AIO-001, a long-acting anti-TSLP monoclonal antibody for adult patients with severe asthma, including those with low T2 inflammation. Aiolos Bio Inc., based in the US, develops innovative treatments targeting unmet needs in respiratory conditions.

Major companies operating in the asthma and chronic obstructive pulmonary disease (copd) drugs market are Sun Pharmaceutical Industries Ltd., Viatris Inc., Hikma Pharmaceuticals PLC, Orion Corporation, Bausch Health Companies Inc., Kyorin Pharmaceutical Co. Ltd., Sandoz International GmbH, Mundipharma International Ltd., Ferrer Internacional S.A., Neopharm Group, Covis Pharma Group, Almirall S.A., Menarini Group, Cipla Health Ltd., Indoco Remedies Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Wockhardt Ltd., Ajanta Pharma Ltd., Emcure Pharmaceuticals Ltd., Abbott Laboratories, Endo International plc, Takeda Pharmaceutical Company Ltd.

North America was the largest region in the asthma and COPD drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (copd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the asthma and chronic obstructive pulmonary disease (copd) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The asthma and COPD drugs market consists of sales of bronchodilators, inhaled corticosteroids, combination inhalers, leukotriene modifiers, biologics, theophylline, and systemic corticosteroids. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses asthma and chronic obstructive pulmonary disease (copd) drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for asthma and chronic obstructive pulmonary disease (copd) drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The asthma and chronic obstructive pulmonary disease (copd) drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Drug Class: Bronchodilators; Corticosteroids; Combination Drugs; Leukotriene Modifiers
2) By Route Of Administration: Inhalation; Oral; Injection; Other Route Of Administrations
3) By Patient Group: Adult; Pediatric; Geriatric
4) By Application: Asthma; Chronic Obstructive Pulmonary Disease
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Drug Stores
Subsegments:
1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA); Long-Acting Beta-2 Agonists (LABA); Anticholinergics; Long-Acting Muscarinic Antagonists; Methylxanthines
2) By Corticosteroids: Inhaled Corticosteroids (ICS); Oral Corticosteroids; Intravenous Corticosteroids
3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid; Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist; Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid
4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists; Leukotriene Synthesis Inhibitors
Companies Mentioned: Sun Pharmaceutical Industries Ltd.; Viatris Inc.; Hikma Pharmaceuticals PLC; Orion Corporation; Bausch Health Companies Inc.; Kyorin Pharmaceutical Co. Ltd.; Sandoz International GmbH; Mundipharma International Ltd.; Ferrer Internacional S.A.; Neopharm Group; Covis Pharma Group; Almirall S.A.; Menarini Group; Cipla Health Ltd.; Indoco Remedies Ltd.; Intas Pharmaceuticals Ltd.; Alembic Pharmaceuticals Ltd.; Torrent Pharmaceuticals Ltd.; Macleods Pharmaceuticals Ltd.; Wockhardt Ltd.; Ajanta Pharma Ltd.; Emcure Pharmaceuticals Ltd.; Abbott Laboratories; Endo International plc; Takeda Pharmaceutical Company Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH5MACOP01_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.3 Industry 4.0 & Intelligent Manufacturing
- 4.1.4 Artificial Intelligence & Autonomous Intelligence
- 4.1.5 Sustainability, Climate Tech & Circular Economy
4.2. Major Trends
- 4.2.1 Increased Use Of Combination Inhaler Therapies
- 4.2.2 Growing Adoption Of Long-Acting Bronchodilators
- 4.2.3 Expansion Of Biologic Therapies For Severe Asthma
- 4.2.4 Shift Toward Home-Based Respiratory Management
- 4.2.5 Rising Demand For Generic Inhalation Drugs

5. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Analysis Of End Use Industries

5.1 Hospitals
5.2 Clinics
5.3 Home Healthcare Settings
5.4 Retail Pharmacies
5.5 Online Pharmacies

6. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Size, Comparisons And Growth Rate Analysis
7.3. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Segmentation

9.1. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers
9.2. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Inhalation, Oral, Injection, Other Route Of Administrations
9.3. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Adult, Pediatric, Geriatric
9.4. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Asthma, Chronic Obstructive Pulmonary Disease
9.5. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores
9.6. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Sub-Segmentation Of Bronchodilators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines
9.7. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids
9.8. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Sub-Segmentation Of Combination Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid
9.9. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Sub-Segmentation Of Leukotriene Modifiers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors

10. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Regional And Country Analysis

10.1. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

11.1. Asia-Pacific Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

12.1. China Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

13.1. India Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

14.1. Japan Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

15.1. Australia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

16.1. Indonesia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

17.1. South Korea Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

18.1. Taiwan Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

19.1. South East Asia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

20.1. Western Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

21.1. UK Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

22.1. Germany Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

23.1. France Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

24.1. Italy Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

25.1. Spain Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

26.1. Eastern Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

27.1. Russia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

28.1. North America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

29.1. USA Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

30.1. Canada Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

31.1. South America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

32.1. Brazil Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

33.1. Middle East Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

34.1. Africa Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Regulatory and Investment Landscape

36. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Competitive Landscape And Company Profiles

36.1. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Company Profiles
- 36.3.1. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Hikma Pharmaceuticals PLC Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Orion Corporation Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Bausch Health Companies Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Other Major And Innovative Companies

Kyorin Pharmaceutical Co. Ltd., Sandoz International GmbH, Mundipharma International Ltd., Ferrer Internacional S.A., Neopharm Group, Covis Pharma Group, Almirall S.A., Menarini Group, Cipla Health Ltd., Indoco Remedies Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Wockhardt Ltd.

38. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

40. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market High Potential Countries, Segments and Strategies

40.1 Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market In 2030 - Countries Offering Most New Opportunities
40.2 Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market In 2030 - Segments Offering Most New Opportunities
40.3 Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations
41.2. Currencies
41.3. Historic And Forecast Inflation Rates
41.4. Research Inquiries
41.5. The Business Research Company
41.6. Copyright And Disclaimer